Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines

Vaccine

Volumn 31, Issue 1, 2012, Pages 190-195

  Couch, Robert B ^a   Atmar, Robert L ^a   Keitel, Wendy A ^a   Quarles, John M ^b   Wells, Janet ^a   Arden, Nancy ^b   Niño, Diane ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

Antibody; Hemagglutinin; Influenza; Neuraminidase; Randomized; Vaccination

Indexed keywords

HEMAGGLUTININ; HEMAGGLUTININ ANTIBODY; INFLUENZA VACCINE; LIVE VACCINE; NEURAMINIDASE ANTIBODY; SIALIDASE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA A (H3N2); MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; VACCINATION;

ADOLESCENT; ADULT; ANTIBODY FORMATION; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA VACCINES; MALE; NEURAMINIDASE; VACCINATION; YOUNG ADULT;

EID: 84870531160     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.10.065     Document Type: Article

References (50)

1. CDC. Prevention and Control of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010;59(No. RR-8).
2. Treanor J.J. Influenza Virus. Principles and practice of infectious diseases 2010, 2065-2088. Churchill Livingstone Elsevier, Philadelphia, Pennsylvania. seventh ed. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
3. Jahiel R.I., Kilbourne E.D. Reduction in plaque size and reduction in plaque number as differing indices of influenza virus-antibody reactions. J Bacteriol 1966, 92:1521-1534.
4. Schulman J.L., Khakpour M., Kilbourne E.D. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol 1968, 2:778-786.
5. Couch R.B., Kasel J.A., Gerin J.L., Schulman J.L., Kilbourne E.D. Induction of partial immunity to influenza using a neuraminidase-specific vaccine. J Infect Dis 1974, 129:411-420.
6. Couch RB, Atmar RL, Franco LM, Quarles JM, Wells J, Arden N, et al. Antibody correlates and predictors of immunity to naturally-occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis 2012, in press.
7. Cate T.R., Rayford Y., Niño D., Winokur P., Brady R., Belshe R., et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2010, 28:2076-2079.
8. Dowdle W.N., Kendal A.P., Noble G.R. Influenza viruses. Diagnostic procedures for viral, rickettsial and chlamydial infections 1979, 603-605. American Public Health Association, Washington, DC. 5th ed. E.H. Lenette, N.J. Schmidt (Eds.).
9. Keitel W.A., Couch R.B., Cate T.R., Hess K.R., Baxter B., Quarles J.M., et al. High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol 1994, 32:2468-2473.
10. Lai J.C.C., Chan W.W.L., Kien F., Nicholls J.M., Peiris J.S.M., Garcia J-M. Formation of virus-like particles from human cell lines exclusively expressing influenza neuraminidase. J Gen Virol 2010, 91:2322-2330.
11. Yondola M.A., Fernandes F., Belicha-Villanueva A., Uccelini M., Gao Q., Carter C., et al. Budding capability of the influenza virus neuraminidase can be modulated by tetherin. J Virol 2011, 85:2480-2491.
12. Chen B.J., Leser G.P., Morita E., Lamb R.A. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J Virol 2007, 81:7111-7123.
13. Clinical studies of influenza vaccines-1976. J Infect Dis supplement 1977;136:S397-742.
14. Clinical studies of influenza vaccines-1978. Rev Infect Dis 1983;5:723-64.
15. Baxter R., Jeanfreau R., Block S.L., Blatter M., Pichichero M., Jain V.K., et al. A phase III evaluation of immunogenicity and safety of two trivalent inactivated seasonal influenza vaccines in US children. Pediatr Infect Dis J 2010, 29:924-930.
16. Specific immunity in influenza-summary of influenza workshop III. J Infect Dis 1973;127:220-36.
17. Influenza vaccines-summary of influenza workshop V. J Infect Dis 1974;129:750-71.
18. Potter C.W., Oxford J.S. Determinants of immunity to influenza infection in man. Br Med Bull 1979, 35:69-75.
19. Couch R.B. An overview of serum antibody responses to influenza virus antigens. Developments in biologicals: laboratory correlates of immunity to influenza 2003, 115:25-30. Karger.
20. Kim H.W., Arrobio J.O., Brandt C.D., Parrott R.H., Murphy B.R., Richman D.D., et al. Temperature-sensitive mutants of influenza A virus: response of children to the influenza A/Hong Kong68-ts-1[E] (H3N2) and influenza A/Udorn/72-5s-1[E] (H3N2) candidate vaccine viruses and significance of immunity to neuraminidase antigen. Pediatr Res 1976, 10:238-242.
21. Monto A.S., Kendal A.P. Effect of neuraminidase antibody on Hong Kong influenza. Lancet 1973, i:623-625.
22. Kendal A.P., Nobel G.R., Dowdle W.R. Neuraminidase content of influenza vaccines and neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. J Infect Dis 1977, 136:S415-S424.
23. Kendal A.P., Bozeman F.M., Ennis F.A. Further studies of the neuraminidase content of inactivated influenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. Infect Immun 1980, 29:966-971.
24. Ogra P.L., Chow T., Beutner K.R., Rubi E., Strussenberg J., DeMello S., et al. Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans. J Infect Dis 1977, 135:499-506.
25. Beutner K.R., Chow T., Rubi E., Strussenberg J., Clement J., Ogra P.L. Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection. J Infect Dis 1979, 140:844-850.
26. Kilbourne E.D., Couch R.B., Kasel J.A., Keitel W.A., Cate T.R., Quarles J.M., et al. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 1995, 13:1799-1803.
27. Powers D.C., Kilbourne E.D., Johansson B.E. Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults. Clin Diagn Lab Immunol 1996, 3:511-516.
28. Muhamed G., Greenbaum E., Zakay-Rones Z. Neuraminidase antibody responses to inactivated influenza virus vaccine following intranasal and intramuscular vaccination. Isr Med Assoc J 2006, 8:155-158.
29. Marcelin G., Bland H.M., Negovetich N.J., Sandbulte M.R., Ellebedy A.H., Webb A.D., et al. Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A (H1N1) 2009 virus in an age-dependent manner. J Infect Dis 2010, 202:1634-1638.
30. Fritz R., Sabarth N., Kiermayr S., Hohenadl C., Howard M.K., Ilk R., et al. A Vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies. J Infect Dis 2012, 205:28-34.
31. Murphy B.R., Kasel J.A., Chanock R.M. Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med 1972, 286:1329-1332.
32. Johansson B.E., Kilbourne E.D. Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition. J Virol 1993, 67:5721-5723.
33. Tanimoto T., Nakatsu R., Fuke I., Ishikawa T., Ishibashi M., Yamanishi K., et al. Estimation of the neuraminidase content of influenza viruses and split-product vaccines by immunochromatography. Vaccine 2005, 23:4598-4609.
34. Webster RG, Krauss S. WHO manual on animal influenza diagnosis and surveillance. [Accessed: 06.09.12]. http://www.who.int/csr/resources/publications/influenza/en/whocdscsrncs20025rev.pdf.
35. Lambre C.R., Terzidis H., Greffard A., Webster R.G. Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates. J Immunol Methods 1990, 135:49-57.
36. Murphy B.R., Rennels M.B., Douglas R.G., Betts R.F., Couch R.B., Cate T.R., et al. Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers. Infect Immun 1980, 29(2):348-355.
37. Keitel W.A., Couch R.B., Cate T.R., Six H.R., Baxter B.D. Cold recombinant influenza B/Texas/1/87 vaccine virus (CRB 87): attenuation, immunogenicity and efficacy against homotypic challenge. J Infect Dis 1990, 161(1):22-26.
38. Talaat K.R., Karron R.A., Liang P.H., McMahon B.A., Luke C.J., Thumar B., et al. An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults. Influenza Other Respi Viruses 2012, 10.1111/j. 1750-2659.2012.00350.x.
39. Wright P.F., Okabe N., McKee Jr K.T., Maassab H.F., Karzon D.T. Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J Infect Dis 1982, 146:71-79.
40. Ashkenazi S., Vertruyen A., Aristegui J., Esposito S., McKeith D.D., Klemola T., et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006, 25:870-879.
41. Fleming D.M., Crovari P., Wahn U., Klemola T., Schlesinger Y., Langussin A., et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006, 25:860-869.
42. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356:685-696.
43. Ohmit S.E., Victor J.C., Rotthoff J.R., Teich E.R., Truscon R.K., Baum L.L., et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006, 355:2513-2522.
44. Ohmit S.E., Victor J.C., Teich E.R., Truscon R.K., Rotthoff J.R., Newton D.W., et al. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis 2008, 198:312-317.
45. Monto A.S., Ohmit S.E., Petrie J.G., Johnson E., Truscon R., Teich E., et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009, 361:1260-1267.
46. Wang Z., Tobler S., Roayaei J., Eick A. Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. JAMA 2009, 301-945-53.
47. Eick A.A., Wang Z., Hughes H., Ford S.M., Tobler S.K. Comparison of the trivalent live attenuated vs. inactivated influenza vaccines among U.S. military service members. Vaccine 2009, 27:3568-3575.
48. Ambrose C.S., Levin M.J., Belshe R.B. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respi Viruses 2010, 5:67-75.
49. Belshe R.B., Toback S.L., Yi T., Ambrose C.S. Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age. Influenza Other Respi Viruses 2010, 4:141-145.
50. Belshe R.B., Gruber W.C., Mendelman P.M., Mehta H.B., Mahmood K., Reisinger K., et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000, 181:1133-1137.